Comment on article by Poostiyan et al.: Tranexamic acid microinjections versus tranexamic acid mesoneedling in the treatment of facial melasma: A randomized assessor‐blind split‐face controlled trial
Journal of Cosmetic Dermatology · 2023
DOI: 10.1111/jocd.15853 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Cosmetic Dermatology, 2023. Verfasst von Menglei Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Tongxiang First People's Hospital, Jiaxing, China. Hauptthemen laut MEDLINE: Antifibrinolytic Agents, Melanosis, Tranexamic Acid. Die Arbeit nennt 3 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Tongxiang First People's Hospital, Jiaxing, China.
- Graduate school, Zhejiang Chinese Medical University, Hangzhou, China.
Zitieren
APA
Wang, M., & Yang, C. (2023). Comment on article by Poostiyan et al.: Tranexamic acid microinjections versus tranexamic acid mesoneedling in the treatment of facial melasma: A randomized assessor‐blind split‐face controlled trial. Journal of Cosmetic Dermatology. https://doi.org/10.1111/jocd.15853
Vancouver
Wang M, Yang C. Comment on article by Poostiyan et al.: Tranexamic acid microinjections versus tranexamic acid mesoneedling in the treatment of facial melasma: A randomized assessor‐blind split‐face controlled trial. Journal of Cosmetic Dermatology. 2023. doi:10.1111/jocd.15853
BibTeX
@article{Wang2023,
author = {Wang, Menglei and Yang, Chenyi},
title = {Comment on article by Poostiyan et al.: Tranexamic acid microinjections versus tranexamic acid mesoneedling in the treatment of facial melasma: A randomized assessor‐blind split‐face controlled trial},
journal = {Journal of Cosmetic Dermatology},
year = {2023},
doi = {10.1111/jocd.15853}
}
EUVIMED